PubMed · 10691582
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
F Muñoz-López. Inhaled corticosteroids?. https://pubmed.ncbi.nlm.nih.gov/10691582/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Because regional chemotherapy has been useful in treatment and palliation of many cancer types, the concept of delivering drugs by inhalation for the treatment of cancers in the lung is attractive. Much higher local drug exposure can be achieved with total doses considerably lower than those required for systemic administration, resulting in lower exposure of nonrespiratory tract tissues to potentially toxic drugs. Regional delivery of chemotherapy to the respiratory tract has been shown to have activity in preclinical and clinical studies. Technical improvements in delivery methods have now made it possible to conduct trials of inhalational agents, both to treat cancers affecting the respiratory tract and to deliver other drugs used in cancer patients. This review discusses the rationale of drug delivery by the inhalational route, its technical challenges, preclinical and clinical experiences, limitations, and promise.
Explore the source record for details and available documents.
OBJECTIVE: To determine whether elderly people can learn to use the inhaler used to deliver zanamivir (Relenza Diskhaler) as effectively as the Turbohaler and to identify which aspects of inhaler technique are most problematic. DESIGN: Randomised, controlled, intervention study. SETTING: Wards for acute elderly care in a large district general hospital. PARTICIPANTS: 73 patients who were unfamiliar with the use of an inhaler, aged 71 to 99 (mean 83) years. MAIN OUTCOME MEASURES: Initial scores and changes in scores 24 hours later using a 10 point scoring system of five aspects of inhaler technique. RESULTS: 38 patients were allocated the Relenza Diskhaler and 35 the Turbohaler. The mean total score was significantly greater in the Turbohaler than Diskhaler groups both initially (8.74 v 7.05) and after 24 hours (8.28 v 5.43). The major difference between inhalers was in loading and priming. After tuition 50% (19 of 38) of patients allocated the Diskhaler were unable to load and prime the device and 65% (24 of 37) were unable to do so 24 hours later. Of those allocated the Turbohaler, two patients were unable to load and prime the device after initial review and one after 24 hours. CONCLUSION: Most elderly people cannot use the inhaler device used to deliver the anti-influenza drug zanamivir. Treatment with this drug is unlikely to be effective in elderly people unless the delivery system is improved.